SRR29022833
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.730
- INTERFERON_GAMMA_RESPONSE+0.690
- ALLOGRAFT_REJECTION+0.630
- E2F_TARGETS+0.570
- IL6_JAK_STAT3_SIGNALING+0.530
- INFLAMMATORY_RESPONSE+0.500
- G2M_CHECKPOINT+0.490
- TNFA_SIGNALING_VIA_NFKB+0.490
- COMPLEMENT+0.390
- MYC_TARGETS_V2+0.380
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.430
- CHOLESTEROL_HOMEOSTASIS-0.420
- FATTY_ACID_METABOLISM-0.400
- OXIDATIVE_PHOSPHORYLATION-0.390
- PEROXISOME-0.390
- ADIPOGENESIS-0.380
- BILE_ACID_METABOLISM-0.350
- UV_RESPONSE_DN-0.330
- ANDROGEN_RESPONSE-0.300
- PROTEIN_SECRETION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-S3-AA10-01A-21R-A41B-07 | — | E | 0.922 |
| 2 | SRR8518367 | — | D | 0.895 |
| 3 | C3N-02922 | — | cohortMD2 | 0.885 |
| 4 | TCGA-A2-A0CM-01A-31R-A034-07 | — | E | 0.884 |
| 5 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.878 |
| 6 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.863 |
| 7 | SRR8518263 | — | D | 0.861 |
| 8 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.858 |
| 9 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.858 |
| 10 | 2dbf638a-46c1-4ec8-b81d-d859c7dcf989 | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.730 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.690 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.630 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |